结外NK/T细胞淋巴瘤现代放疗:风险适配治疗、靶区与剂量指南
国际淋巴瘤放射肿瘤学组发布共识,针对早期结外鼻型NK/T细胞淋巴瘤,明确放疗是最有效手段且为综合治疗必要组成部分;指南聚焦临床特征异质性、风险适配治疗原则及放疗设计,包括靶区定义、剂量与实施方法,并依据原发部位将临床靶区分为鼻型、非鼻上呼吸消化道型和上呼吸消化道外型。
要点
- 早期ENKTCL根治性治疗中放疗最有效,是综合治疗必要组成。
- 推荐采用风险适配治疗原则,并遵循受累部位放疗原则。
- 临床靶区常较其他淋巴瘤更广,需覆盖原发肿瘤浸润、多发病灶或广泛黏膜下浸润。
核心结论
- 放疗是早期结外鼻型NK/T细胞淋巴瘤最有效的根治性手段,也是综合治疗的必要组成部分。
研究设计与样本
- 国际淋巴瘤放射肿瘤学组基于共识制定指南,聚焦临床特征异质性、风险适配治疗原则及放疗作用与设计。
主要发现
- 近十年前瞻性放疗联合非蒽环类化疗改善了该病的治疗与预后。
- 放疗方法(靶区定义、剂量与实施方式)对优化早期患者治愈至关重要。
- 临床靶区因原发肿瘤浸润、多发病灶或广泛黏膜下浸润而常较其他淋巴瘤更广。
- 临床靶区按原发部位主要分为鼻型、非鼻上呼吸消化道型和上呼吸消化道外型。
关键数值与推荐
- 指南就放疗方法、靶区定义、最佳剂量与剂量约束形成共识推荐。
临床怎么用
- 早期ENKTCL应采用风险适配的综合治疗策略,放疗作为核心手段。
- 靶区勾画应遵循受累部位放疗原则,并根据原发部位分型确定临床靶区范围。
- 需关注原发肿瘤浸润、多发病灶及黏膜下浸润对靶区外扩的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the multidisciplinary management of early-stage extranodal natural killer/T-cell lymphoma, nasal type (ENKTCL), with curative intent, radiation therapy is the most efficacious modality and is an essential component of a combined-modality regimen. In the past decade, utilization of upfront radiation therapy and non-anthracycline-based chemotherapy has improved treatment and prognosis. This guideline mainly addresses the heterogeneity of clinical features, principles of risk-adapted therapy, and the role and appropriate design of radiation therapy. Radiation therapy methods (including target volume definition, dose and delivery methods) are crucial for optimizing cure for patients with early-stage ENKTCL. The application of the principles of involved site radiation therapy in this lymphoma entity often leads to a more extended clinical target volume (CTV) than in other lymphoma types because it usually presents with primary tumor invasion, multifocal lesions, or extensive submucosal infiltration beyond the macroscopic disease. The CTV varies across different primary sites and is classified mainly into nasal, nonnasal upper aerodigestive tract (UADT), and extra-UADT entities. This review is a consensus of the International Lymphoma Radiation Oncology Group regarding the approach to radiation therapy, target-volume definition, optimal dose, and dose constraints in ENKTCL treatment.
引用
- Qi SN, Li YX, Specht L, et al. Modern Radiation Therapy for Extranodal Nasal-Type NK/T-cell Lymphoma: Risk-Adapted Therapy, Target Volume, and Dose Guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2021. PMID: 33581262. doi:10.1016/j.ijrobp.2021.02.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。